AGENTS FOR USE IN THE THERAPEUTIC OR PROPHYLACTIC TREATMENT OF MYOPIA OR HYPEROPIA

摘要

The present invention relates to the prophylactic or therapeutic treatment of myopia in a subject, which is capable of directly or indirectly reducing epidermal growth factor receptor (EGFR) signaling and/or signaling of other receptors sensitive to amphiregulin in the subject. It relates to a formulation for use in the city. The present invention also provides for use in prophylactic or therapeutic treatment of hyperopia in a subject, which may increase epidermal growth factor receptor (EGFR) signaling and/or signaling of other receptors sensitive to amphiregulin in the subject. It is about the formulation. The present invention also provides a method comprising the steps of: (a) providing a biological sample from a subject; (b) measuring the level of amphiregulin in the sample; (c) comparing the level determined in step (b) with the level of amphiregulin found in the subject who is emmetropic or will be emmetropic; and (d) determining that the subject has or may cause the onset of myopia if the level measured in step (b) is higher than the amphiregulin level found in the subject who is or will become emmetropic, ; In a subject, comprising determining that the level measured in step (b) is lower than the amphiregulin level found in a subject who is or will become emmetropic, has hyperopia or may cause the development of hyperopia. It relates to a method for diagnosing myopia or farsightedness. Finally, the present invention relates to methods for identifying agents associated with amphiregulin or fragments or variants thereof.